Back to Newsroom

Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union

Company on track to complete Phase 2 study in cystic fibrosis in 2016; Phase 2 topline results expected Q1 2017

NORWOOD, MA — (Marketwired) — 10/18/16 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union for the Company’s novel synthetic oral endocannabinoid-mimetic drug,Resunab, for the treatment of cystic fibrosis (“CF”).

Click here to read the full release